Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force

The 2020 COVID-19 pandemic has disrupted Alzheimer’s disease (AD) clinical studies worldwide. Digital technologies may help minimize disruptions by enabling remote assessment of subtle cognitive and functional changes over the course of the disease. The EU/US Clinical Trials in Alzheimer’s Disease (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaye, Jeffrey, Aisen, P., Amariglio, R., Au, R., Ballard, C., Carrillo, M., Fillit, H., Iwatsubo, T., Jimenez-Maggiora, G., Lovestone, S., Natanegara, F., Papp, K., Soto, M. E., Weiner, M., Vellas, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
CTAD Task Force Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244451/
https://www.ncbi.nlm.nih.gov/pubmed/34585227
http://dx.doi.org/10.14283/jpad.2021.36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244451/
https://www.ncbi.nlm.nih.gov/pubmed/34585227
http://dx.doi.org/10.14283/jpad.2021.36

Ejemplares similares